최종 결과
본 발표에는 7년 유럽 연합(탈퇴)법에 따라 영국 법률의 일부를 구성하는 규정 2014/596/EU 제2018조의 목적을 위한 내부 정보가 포함되어 있습니다. 본 발표가 발표될 때 이 내부 정보는 이제 공개 도메인에 있는 것으로 간주됩니다.
25 4월 2024
헤모제닉스 파마슈티컬스 PLC
("헤모제닉스 파마슈티컬스" 또는 "회사")
최종 결과
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2023. The Annual Report is available to view on the Company's web site at https://hemogenyx.com.
주요 하이라이트
· Investigational New Drug ("IND") application submitted in May 2023 seeking authorisation from the U.S. Food and Drug Administration ("FDA") to begin a Phase I clinical trial of HEMO-CAR-T for treating acute myeloid leukaemia (AML)
· After a clinical hold period, to address manufacturing issues, HEMO-CAR-T was granted authority from the FDA in February 2024 to commence Phase I clinical trials
· Continuing development of Chimeric Bait Receptor ("CBR") antiviral/biodefence platform and filed a patent application entitled Chimeric Bait Receptors and Uses Thereof
· Successfully raised £5.25 million (before expenses) in total through the allotment and issue of new ordinary shares during the year ended 31 December 2023, and a further £3.25 million in early 2024
· Entered into agreement with Prevail InfoWorks Inc. to provide clinical services and technologies for the Company's upcoming Phase I clinical trial of HEMO CAR-T
이러한 발전에 대한 자세한 내용은 아래 의장 성명에 포함되어 있습니다.
회장 성명서
I am pleased to report the Company's results for the year ended 31 December 2023. The period was a vital one in the progression of the Company. Development work on our lead HEMO-CAR-T product candidate was completed and we were able to submit an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") to enable us to move into clinical trials for HEMO-CAR-T. Unfortunately, the FDA decided that certain aspects of the data initially provided did not meet its rigorous safety standards, so it imposed a clinical hold pending further development of the product. We worked hard in the final months of the year to meet the FDA's additional requirements and, as a result, the clinical hold was lifted in January 2024. Hemogenyx Pharmaceuticals is thereby established as a "clinical stage" company and we are now proceeding to the next step in the development of HEMO-CAR-T, the commencement of Phase I clinical trials.
â € <
At the same time, we continued to move forward, insofar as funding would allow, with our other main pipeline assets, our Chimeric Bait Receptor ("CBR") platform and our CDX bi-specific CD3-FLT3 antibody ("CDX"). Significant progress was made on the former, as will be described more fully below.
â € <
기금 모금
â € <
We raised capital on a number of occasions in the period under review.
â € <
In January 2023, we were successful in raising £4,056,250 in new equity capital at 2.5p per share which was intended to take us through the IND process and to the stage of clinical trials for HEMO-CAR-T. The clinical hold delayed matters for some months and of course diminished our cash resources. In December 2023, we therefore raised a further £534,375 at 2.375p per share to take us to the next key stage.
â € <
In September, Prevail Partners LLC ("Prevail Partners") made a strategic investment of $830,000 (£680,000) through a subscription for 11,066,067 new ordinary shares in the Company at a price of $0.075 (about 6p), at a premium of approximately 240% to the then share price. Prevail Partners is the investment partner of Prevail Infoworks Inc. ("Infoworks"), a contract research organisation that we have engaged to provide a variety of services necessary for the implementation and management of the clinical trials of HEMO-CAR-T. The price at which Prevail Partners made its investment in Hemogenyx Pharmaceuticals demonstrated its confidence in our HEMO-CAR-T product candidate. Further information on our association with Prevail Partners and Infoworks is described in the section headed "HEMO-CAR-T" below.
â € <
Since the period end, and following the lifting of the clinical hold, we raised a further £3.325 million at 2p per share to enable us to move into clinical trials.
â € <
While we accept that recent market conditions have been very difficult, we have been disappointed by the successively lower price at which we have had to carry out our fundraisings in the UK market, in the light of the progress we have made and the view taken by Prevail Partners concerning our status. The capital recently raised will undoubtedly take us materially further forward and we are now looking at a number of strategies for the future development of all three of our current product candidates.
â € <
기간의 결과
â € <
The Group incurred a loss for the year to 31 December 2023 of £6,696,493 (31 December 2022: £3,986,982 loss).
In the year to 31 December 2023 the loss mainly arose from operational expenses pursuing the Group's objectives listed in the Strategic Report on page 10, as well as salaries, consulting and professional fees, and general administration expenses. These expenses have been met from the proceeds of equity placings that were undertaken during the period, as further detailed in the Fundraising section above.
â € <
헤모카-T
The principal objective of HEMO-CAR-T is, as shareholders will know, to provide a new and more effective treatment and potential cure for relapsed and/or refractory acute myeloid leukaemia ("R/R AML").
AML is the most common type of acute leukaemia in adults and has poor survival rates; it is currently treated using chemotherapy, rather than the potentially more benign and effective form of cell therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.
Development work on HEMO-CAR-T was largely completed during 2022 and work in 2023 was mainly devoted to preparing the IND application to the FDA, an essential step before being able to commence clinical trials. The FDA's concern, as shareholders will be aware, is primarily with the safety of a treatment, and it rightly works to a very high standard. The work in preparing the IND application was extremely detailed and resulted in an application document running to over 3,000 pages. It was finally submitted in May 2023. As mentioned above, the FDA was not satisfied with a particular aspect of the detail provided and therefore imposed a clinical hold on the HEMO-CAR-T programme in June. Our scientific team worked on resolving the matter through the latter part of the year and on remanufacturing of the CAR-T components. This resulted in the clinical hold being lifted in January 2024. Although this was a setback, it is important to say that the FDA's concerns were limited to one issue, and we were able to satisfy them much more quickly than many other companies whose prospective treatments were put on clinical hold.
The removal of the clinical hold has enabled us to proceed with taking HEMO-CAR-T into clinical trials with the objective of getting an initial patient injected in the coming months. The Company has been actively putting the necessary pieces in place for some time, including discussions with the Hospital of the University of Pennsylvania, one of the leading cancer treatment hospitals in the US, in order to initiate the clinical trials process.
Also, crucially, in September 2023, Hemogenyx Pharmaceuticals contracted with Infoworks, a well-established and experienced contract research organisation ("CRO"), through a Master Services and Contract Agreement for Infoworks to provide clinical services and technologies for the forthcoming Phase I clinical trials over an initial term of 40 months. An initial work plan was agreed, including clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, with the use of InfoWorks' integrated real-time data analytics platform for clinical support and real-time analysis. This vital link brings us Infoworks' operational expertise and will ensure smooth execution of the clinical trials and fast, reliable data to lower our clinical risk and speed up our regulatory timeline.
At the same time, Prevail Partners, the investing affiliate of Infoworks, made the investment at a premium in the Company described more fully in the section headed "Fundraising" above.
Chimeric Bait Receptor
While our Chimeric Bait Receptor ("CBR") was initially envisaged as a potential cure for a very wide range of viral diseases, it has recently become clear that it is also potentially a viable approach for the treatment of a range of cancers. The development of CBR as a cure for viral infections continues, and we remain excited about that, but its potential efficacy against cancer may provide a quicker route to successful development, approval and use.
While we have had limited resources to apply to the development of our proprietary CBR technology platform, there have been a number of key developments and discoveries during the period under review and in the early part of 2024. We have been able to achieve as much as we have done because development of novel CBR constructs is facilitated and accelerated by 실리에 simulations using Artificial Intelligence ("AI") tools and pipelines. In the wake of the COVID-19 pandemic, and in the face of global threats of emerging as well as engineered biological threats, the need for a nimble and proactive solution against future infectious agents became clear. We developed CBR as a novel, highly innovative, and patented immunotherapy initially for COVID-19. However, CBR has been designed to prevent and defeat infection by any known or emerging virus, potentially subverting the next global pandemic, and rendering virally-engineered bioweapons ineffective. To achieve proof of concept, we successfully designed a CBR construct ("CBR-COVID19") to programme macrophages to neutralise the SARS-CoV-2 virus. We have also demonstrated that CBR-COVID19 is insensitive to several known variants of SARS-CoV-2 that make the original SARS-CoV-2 virus more infectious and challenge existing vaccine approaches. We are testing the efficacy of CBR-COVID19 against live infectious replicating SARS-CoV-2 virus in a major Biosafety Level 3 facility.
One of the ultimate threats from emerging viruses, whether natural or man-made, is their uncertainty and unpredictability. Current therapeutic responses require extensive knowledge of the agent(s) as well as time-consuming and duplicative research efforts to develop effective treatments after an outbreak has begun. In this light, our first-in-class CBR platform allows for minimal lead time between first infection or pre-emptive intelligence and first response, providing protection for those on the front line of such a threat at a scale that has thus far not been achieved.
As we announced in February 2024, CBR in relation to viruses is innovative in three ways: it will be an off-the-shelf therapeutic against airborne viral infections, it will be effective against emerging mutations of the targeted viruses, and it will be able to be stored, deployed and administered in the field using a standard atomiser/inhaler. These innovative features have been tested in the laboratory, and the ability of CBR to be delivered intranasally in spray form has been tested by our scientists 생체내에서 in small animals. This recent work on the intranasal delivery of CBR is a breakthrough, enabling its development as an off-the-shelf prevention and/or treatment that will be cost-effective and simple to administer, making it ideal for the protection both of the civilian population and in biodefence.
Moving onto cancer-related CBR innovations, we have found that a number of difficult conditions can potentially be treated using CBR. We have established that macrophages programmed with CBR have several potential advantages compared to other existing anti-cancer therapies. Our studies suggest that they can, 그 중에서도, penetrate solid tumours, provide a better safety profile for treatment, and potentially cross the blood-brain barrier to target brain cancers and/or certain neurodegenerative diseases.
As announced last November, we have now demonstrated that CBR could be used effectively in the treatment of a number of cancer conditions, in particular that CBR-programmed macrophages show promise for treatment of Non-Hodgkin Lymphoma ("NHL"). Our scientists have demonstrated that human macrophages, a type of immune cells, programmed with a purpose designed CBR, are able to eliminate NHL-derived cells with high efficiency 체외에서. This result suggests that the Company may be able to develop an efficient treatment for people suffering from relapsed and/or refractory stage III/IV metastasized NHL. Our work also suggests that such CBRs can also be adapted to target several solid tumours such as epithelial ovarian cancer. NHL is the eleventh most common cancer in humans, with a poor rate of recovery and cure from present treatments. There are currently an estimated 540,000 new cases diagnosed globally with an estimated 260,000 deaths per year. The successful development of a new CBR-related therapy for NHL could have a major impact on treatment and survival rates for the disease.
Our work further suggests that such CBRs can be adapted to target several solid tumours such as epithelial ovarian cancer. We have also begun to see evidence that a CBR-based approach may also potentially be effective against certain neurodegenerative diseases, some of which are currently very difficult or impossible to treat, including possibly Alzheimer's disease. In this regard, in February 2024 we announced a further significant development for CBR, this time in relation to brain cancers and potentially to neurodegenerative diseases. We have established that CBR can be delivered into the brain via programmed microglial cells. Delivery of therapeutics across the blood-brain barrier is one of the most difficult problems in the treatment of brain diseases. Our scientists have developed a means of transplanting human blood stem cells ("HSC") that allows their engraftment and differentiation into immune cells that reside in the brain, carrying out their work 생체내에서 in the brains of immune-compromised mice. We believe that HSCs genetically modified to make CBR and transplanted back into a patient would give rise to microglial cells which could potentially find and destroy brain cancer cells.
Meanwhile, we continue to look to our patent position and, in September 2023, our patent application for CBR with the World Intellectual Property Organization was published, though it remains to be approved.
In summary, we should say that the considerable potential breadth and versatility of CBR has become increasingly evident over the past fifteen months, and evidence of its practical viability has been considerably established. It is not too much to say that CBR, which we always considered to have great potential, can now be seen as possibly revolutionary, now that its widespread probable applicability to difficult or presently untreatable conditions is being established in multiple preclinical studies.
CDX bi-specific antibody
CDX remains an important part of the Company's product candidate portfolio, although it remains to a certain extent in abeyance while we push on with HEMO-CAR-T. However, some steps have been taken with CDX, including approval of the patent application in the USA entitled "Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) in a Patient Using Bi-specific Antibodies" as patent No. 11,945,866. This is a significant addition to the patent protection for CDX, which remains one of our key product candidates for the future. It also solidifies the Company's position as a leader in the area of conditioning of patients for bone marrow transplants.
결론
It remains for me to thank the Board and our strong, highly committed group of scientists for their hard and effective work, and to look forward to another successful year in the future development of Hemogenyx Pharmaceuticals in this new phase as a clinical-stage company.
마크 펠드만 교수 AC, FRS
MB 학사, 박사, FRCP, FRCPath, FAA, F Med Sci
의장
문의 :
헤모제닉스 파마슈티컬스 PLC | https://hemogenyx.com |
Vladislav Sandler 박사, CEO 겸 공동 창립자 | |
피터 레드몬드 (감독) | |
SP Angel 기업 금융 LLP | 전화 : + 44 (0) 20 3470 0470 |
매튜 존슨, 바딤 알렉산드르, 아담 카울 | |
피터하우스 캐피탈 리미티드 | 전화 : + 44 (0) 20 7469 0930 |
루시 윌리엄스, 던컨 베이시, 찰스 굿펠로우 |
연결포괄손익계산서
그룹 - 계속 운영 | 31년 2023월 XNUMX일 종료 | 31년 2022월 XNUMX일 종료 |
|
| |
|
£ |
£ |
수익 | - | - |
|
| |
관리비 | (5,820,165) | (3,433,476) |
감가상각비 | (645,681) | (564,072) |
|
| |
운영 손실 | (6,465,846) | (3,997,548) |
|
| |
금융 수입 | 85,344 | 10,599 |
금융 비용 | (315,991) | (33) |
| ||
과세 전 손실 | (6,696,493) | (3,986,982) |
|
| |
소득세 | - | - |
|
| |
올해의 손실 | (6,696,493) | (3,986,982) |
|
| |
다음으로 인한 손실 : |
| |
- Hemogenyx Pharmaceuticals plc의 소유자 | (6,690,678) | (3,979,314) |
- 비 지배 지분 | (5,815) | (7,668) |
| (6,696,493) | (3,986,982) |
|
| |
후속 적으로 당기 손익으로 재 분류 될 수있는 항목 : |
| |
해외 작업 번역 | 903,067 | (954,642) |
기타 포괄 손익 | 903,067 | (954,642) |
|
| |
해당 연도의 총 포괄 손실 | (5,793,426) | (4,941,624) |
| ||
원인 : |
| |
Hemogenyx Pharmaceuticals plc의 소유자 | (5,787,611) | (4,933,956) |
비 지배 지분 | (5,815) | (7,668) |
해당 연도의 총 포괄 손실 | (5,793,426) | (4,941,624) |
| ||
회사의 주주에게 귀속되는 기본 및 희석주당이익손실 |
(0.006) |
(0.005) |
|
연결 재무 상태 표
그룹 |
31 12월 2023 |
31 12월 2022 |
|
| |
자산 | £ | £ |
비유동 자산 | ||
재산, 식물 및 장비 | 966,423 | 1,023,252 |
사용권 자산 | 2,346,015 | 2,892,261 |
보증금 | 153,668 | 140,821 |
무형 자산 | 470,173 | 441,493 |
비유동 자산 | 3,936,279 | 4,497,827 |
| ||
유동 자산 |
| |
매출 채권 및 기타 채권 | 922,013 | 62,024 |
현금 및 현금성 자산 | 1,247,601 | 2,532,758 |
총 유동 자산 | 2,169,614 | 2,594,782 |
| ||
총자산 | 6,105,893 | 7,092,609 |
|
| |
자산 및 부채 |
| |
주주 귀속 자본 |
| |
납입자본금 |
| |
소집된 자본금 | 11,755,660 | 9,797,493 |
프리미엄 공유 | 19,938,556 | 16,808,647 |
기타 준비금 | 1,164,637 | 921,801 |
역자산취득적립금 | (6,157,894) | (6,157,894) |
외화 환산 준비금 | (77,496) | (980,563) |
이익 잉여금 | (23,804,734) | (17,114,056) |
회사의 소유주에게 귀속되는 자본 | 2,818,729 | 3,275,428 |
비 지배 지분 | (37,723) | (31,908) |
총 자본 | 2,781,006 | 3,243,520 |
| ||
부채 |
| |
비유동 부채 |
| |
리스 부채 | 2,672,802 | 3,100,678 |
비유동 부채 | 2,672,802 | 3,100,678 |
| ||
유동 부채 |
| |
매입 채무 및 기타 채무 | 379,001 | 426,254 |
리스 부채 | 273,084 | 322,157 |
총 유동 부채 | 652,085 | 748,411 |
| ||
총 부채 | 3,324,887 | 3,849,089 |
| ||
총 지분 및 부채 | 6,105,893 | 7,092,609 |
회사 재무상태표
기업 정보 |
31 12월 2023 |
31 12월 2022 |
|
| |
| £ | £ |
자산 | ||
비유동 자산 | ||
자회사 대출 | 18,097,857 | 14,451,733 |
자회사 투자 | 8,000,000 | 8,000,000 |
비유동 자산 | 26,097,857 | 22,451,733 |
| ||
유동 자산 |
| |
매출 채권 및 기타 채권 | 14,820 | 20,405 |
현금 및 현금성 자산 | 219,236 | 88,909 |
총 유동 자산 | 234,056 | 109,314 |
| ||
총자산 | 26,331,913 | 22,561,047 |
|
| |
자산 및 부채 |
| |
주주 귀속 자본 |
| |
외화 환산 준비금 |
| |
납입자본금 |
| |
소집된 자본금 | 11,755,660 | 9,797,493 |
프리미엄 공유 | 19,938,556 | 16,808,647 |
기타 준비금 | 1,163,533 | 920,697 |
이익 잉여금 | (6,721,085) | (5,100,447) |
총 자본 | 26,136,664 | 22,246,390 |
| ||
부채 |
| |
유동 부채 |
| |
매입 채무 및 기타 채무 | 195,249 | 134,657 |
총 유동 부채 | 195,249 | 134,657 |
| ||
총 부채 | 195,249 | 134,657 |
| ||
총 지분 및 부채 | 26,331,913 | 22,561,047 |
Hemogenyx Pharmaceuticals plc has used the exemption granted under s408 of the Companies Act 2006 that allows for the non-disclosure of the Income Statement of the parent company. The after-tax loss attributable to Hemogenyx Pharmaceuticals plc for the year ended 31 December 2023 was £1,620,638 (2022: profit of £1,202,014).
연결 자본 변동표
그룹 | ||||||||
|
| |||||||
자본금 소집 | 프리미엄 공유 |
기타 준비금 |
역취득준비금 | 외화 환산 준비금 | 이익 잉여금 |
비 - 이해관계 통제 | 총 자본 | |
£ | £ | £ | £ | £ | £ | £ | £ | |
1년 2022월 XNUMX일 현재 | 9,797,493 | 16,808,647 |
904,226 |
(6,157,894) |
(25,921) |
(13,134,742) |
(24,240) |
8,167,569 |
연간 손실 | - | - |
- |
- |
- | (3,979,314) |
(7,668) | (3,986,982) |
기타 포괄 소득 | - | - |
- |
- |
(954,642) | - |
- | (954,642) |
당해 년도 총 포괄 이익 | - | - |
- |
- |
(954,642) | (3,979,314) |
(7,668) | (4,941,624) |
옵션 확장 |
- |
- |
17,575 |
- |
- | - |
- | 17,575 |
31 년 2022 월 XNUMX 일 기준 | 9,797,493 | 16,808,647 |
921,801 | (6,157,894) | (980,563) |
(17,114,056) |
(31,908) | 3,243,520 |
연간 손실 | - | - |
- |
- |
- | (6,690,678) |
(5,815) | (6,696,493) |
기타 포괄 소득 | - | - |
- |
- |
903,067 | - |
- |
903,067 |
당해 년도 총 포괄 이익 | - | - |
- |
- |
903,067 | (6,690,678) |
(5,815) | (5,793,426) |
주식의 발행 | 1,958,167 | 3,296,458 | - | - | - | - | - | 5,254,625 |
자본 비용 | - | (166,549) | - | - | - | - | - | (166,549) |
옵션 발행 | - | - | 242,836 | - | - | - | - | 242,836 |
31 년 2023 월 XNUMX 일 기준 | 11,755,660 | 19,938,556 |
1,164,637 |
(6,157,894) |
(77,496) | (23,804,734) |
(37,723) | 2,781,006 |
|
|
|
|
|
|
|
|
|
회사 자본 변동 내역서
기업 정보
| 자본금 소집 | 프리미엄 공유 | 외화 환산 준비금 | 기타 준비금 | 이익 잉여금 | 총 자본 |
| £ | £ | £ | £ | £ | £ |
31 년 2021 월 XNUMX 일 기준 | 9,797,493 | 16,808,647 |
- |
903,122 | (6,302,461) | 21,206,801 |
해당 연도 소득 | - | - |
- |
- | 1,202,014 | 1,202,014 |
기타 포괄 소득 | - | - |
- |
- | - | - |
당해 년도 총 포괄 이익 | - | - |
- |
- | 1,202,014 | 1,202,014 |
옵션 발행 | - | - | - | 17,575 | - | 17,575 |
31 년 2022 월 XNUMX 일 기준 | 9,797,493 | 16,808,647 |
- |
920,697 | (5,100,447) | 22,426,390 |
연간 손실 | - | - |
- |
- | (1,620,638) | (1,620,638) |
기타 포괄 소득 | - | - |
- |
- | - | - |
당해 년도 총 포괄 이익 | - | - |
- |
- | (1,620,638) | (1,620,638) |
주식의 발행 | 1,958,167 | 3,296,458 | - | - | - | 5,254,625 |
자본 비용 | - | (166,549) | - | - | - | (166,549) |
옵션 발행 | - | - | - | 242,836 | - | 242,836 |
|
|
|
|
|
|
|
31 년 2023 월 XNUMX 일 기준 | 11,755,660 | 19,938,556 |
- |
1,163,533 | (6,721,085) | 26,136,664 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
연결 현금 흐름표
그룹 | 끝나는 연도 31 12월 2023 | 끝나는 연도 31 12월 2022 |
|
| |
£ | £ | |
영업활동으로 발생하는 현금흐름 | ||
소득세 전 손실 | (6,696,493) | (3,986,982) |
감가 상각 | 645,681 | 195,246 |
기타 비 현금 항목 | 81 | 81 |
이자 소득 | (85,344) | (10,599) |
이자 비용 | 315,991 | 33 |
공유 기반 지불 | 242,836 | 17,575 |
사용권자산과 리스부채의 순변동 | 306,759 | 627,515 |
외환 이득 (손실) | (1,485) | 12,937 |
(감소)/매매대금 및 기타채무의 증가 | 28,579 | (27,120) |
매출채권 및 기타수취채권의 감소/(증가) | 4,469 | (2,109) |
Decrease/(Increase) in prepaid and deposits | (866,644) | 271,819 |
|
| |
영업활동에 사용된 순현금유출 | (6,105,570) | (2,910,604) |
| ||
재무활동에서 창출된 현금흐름 |
| |
Proceeds from issuance equity securities, net of issue costs | 5,088,076 | - |
리스 부채의 지불 | (638,765) | (110,144) |
| ||
재무 활동에서 창출/사용된 순현금흐름 | 4,449,311 | (110,144) |
| ||
투자 활동으로 창출된 현금 흐름 |
| |
이자 소득 | 85,344 | 10,599 |
임대 보증금 지불 | - | (1,908) |
자산 및 장비 구매 | (117,285) | (428,945) |
|
| |
투자 활동에 사용 된 순 현금 흐름 | (31,941) | (420,254) |
| ||
현금 및 현금 등가물의 순 감소 | (1,688,200) | (3,432,002) |
| ||
환율이 현금에 미치는 영향 | 403,043 | (876,209) |
| ||
연초의 현금 및 현금성자산 | 2,532,758 | 6,840,969 |
현금 및 현금성자산 연말정산 | 1,247,601 | 2,532,758 |
회사 현금 흐름표
기업 정보 | 31년 2023월 XNUMX일 종료 | 31년 2022월 XNUMX일 종료 |
|
| |
| £ | £ |
영업활동으로 발생하는 현금흐름
| ||
(Loss)/gain before income tax
| (1,620,638) | 1,202,014 |
| ||
외환 이득 | 910,832 | (1,539,778) |
공유 기반 지불 | 242,836 | 17,575 |
매출채권 및 기타채권의 증가/(감소) | 5,585 | (4,927) |
거래 및 기타 미지급금의 증가 | 60,592 | 228 |
| ||
영업활동에 사용된 순현금유출 | (400,793) | (324,888) |
| ||
재무활동에서 창출된 현금흐름 |
| |
Proceeds from issuance of equity securities, net of issue costs | 5,088,076 | - |
| ||
재무활동으로 발생한 순현금흐름 | 5,088,076 | - |
| ||
투자 활동에서 창출/사용된 현금 흐름 |
| |
Loan (to)/from related parties | (4,556,312) | 301,421 |
|
| |
순현금흐름(사용)/투자 활동에서 창출 | (4,556,312) | 301,421 |
| ||
현금및현금성자산의 순증가/(감소) | 130,971 | (23,467) |
| ||
환율이 현금에 미치는 영향 | (644) | 1,131 |
| ||
연초의 현금 및 현금성자산 | 88,909 | 111,245 |
현금 및 현금성자산 연말정산 | 219,236 | 88,909 |
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.